SCHEMBL6879859

SCHEMBL6879859

O=C1Nc2cccnc2/C1=C\Nc1ccc(O)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.46
CDK5 Q00535 3/20 0.46
NTRK1 P04629 2/20 0.46
NTRK3 Q16288 2/20 0.46
NTRK2 Q16620 2/20 0.46
CHEK2 O96017 2/20 0.46
CDK1 P06493 2/20 0.46
SRC P12931 2/20 0.46
CSNK2A1 P68400 2/20 0.46
MAPT P10636 2/20 0.46
KDR P35968 2/20 0.46
AURKA O14965 2/20 0.46
HDAC6 Q9UBN7 1/20 0.46
MEN1 O00255 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
INSR P06213 1/20 0.46
LCK P06239 1/20 0.46
LYN P07948 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6879863 1.00 GSK3B (0.46) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL6882552 0.81 RAF1 (0.47) GSK3BNTRK1CHEK2CDK1SRC
SCHEMBL6882549 0.81 RAF1 (0.47) GSK3BNTRK1CHEK2CDK1SRC
SCHEMBL7689471 0.77 KDM4E (0.44) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL7689469 0.77 KDM4E (0.44) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL5873903 0.76 MAPT (0.40) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL5873898 0.76 MAPT (0.40) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL5873909 0.75 ALDH1A1 (0.53) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL5873908 0.75 ALDH1A1 (0.53) GSK3BCDK5NTRK1NTRK3NTRK2
SCHEMBL5873875 0.74 MAPT (0.42) GSK3BCDK5NTRK1NTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX GSK3B 256/4885CDK5 250/4885NTRK1 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.